Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group

Murakami, Tomoya; Okamoto, Fumiki; Kinoshita, Takamasa; Shinomiya, Kayo; Nishi, Tomo; Obata, Shumpei; Ogura, Shuntaro; Nishihara, Yuka; Tsukitome, Hideyuki; Jujo, Tatsuya; Ueda, Kaori; Ishii, Ryota; Oshika, Tetsuro

doi:10.1038/s41433-023-02559-z

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we found no significant difference in BCVA between eyes treated with anti-VEGF and laser therapies, which is consistent with previous studies 20,22,26,27 exploring long-term treatment outcomes for ROP. These results align with the outcomes of our previous multicenter study, where we demonstrated that in Zone I ROP cases, anti-VEGF therapy significantly improved BCVA compared with laser treatment.…”

Section: Discussionsupporting

confidence: 92%

“…Conversely, for Zone II ROP, BCVA did not differ significantly between the two groups. 26 In patients with BW <500 g, anti-VEGF therapy may potentially offer improved BCVA in Zone I ROP; however, because of the small sample size of the present study, subgroup analyses separated by zone were not feasible.…”

Section: Discussionmentioning

confidence: 77%

“…In the previous multicenter study 26 (mean BW = 795 g), the mean SE was −1.77 in the laser group and −1.09 in the anti-VEGF group. In other previous studies (mean BW were 765 g, 15 1,248 g, 20 840 g, 21 and 1,490 g 22 ), the mean SE values in the laser group were −0.87, 0.13, −3.49, and −0.2 D and those in the anti-VEGF group were −0.04, 0.31, −0.16, and −0.9 D, respectively.…”

Section: Discussionmentioning

confidence: 79%

“…We previously reported 26 a multicenter study from the Japan Clinical Retina Study group on 5-year outcomes for ROP, which include participants from this study and patients with BW ≥500 g (264 eyes, mean BW = 795 g). In that study, the mean BCVA was 0.17 logMAR for all eyes, 0.15 in the laser group, and 0.21 in the anti-VEGF group, which were relatively better than the results of this study (0.27, 0.28, and 0.26, respectively).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Five-year visual outcome of treatment for retinopathy of prematurity in infants weighing less than 500 g at birth: A multicenter cohort study from J-CREST

Tomioka,

Murakami,

Okamoto

et al. 2023

Retina

Self Cite

View full text Add to dashboard Cite

Purpose: To investigate the 5-year treatment outcomes of retinopathy of prematurity (ROP) in infants <500 g birth weight and compare laser and anti-vascular endothelial growth factor (VEGF) therapies. Methods: A multicenter retrospective study comprised 24 eyes of 13 patients treated for type 1 ROP, followed for 5 years. Initial treatment was laser and anti-VEGF in 13 and 11 eyes, respectively. Data collected included sex, birth characteristics, ROP characteristics at the time of treatment, best-corrected visual acuity (BCVA), spherical equivalent (SE), and astigmatism at 5 years post-treatment. Results: Median BCVA was 0.15 logMAR (IQR, 0.0–0.5). Snellen BCVA was ≥20/40 in 73% and ≥20/20 in 27% of eyes. Median SE was -2.37 (IQR, -6.1–-0.1); 75% had myopia (≤ -0.5 D), and 25% had high myopia (≤ -6.0 D). Median astigmatism was 1.25 (IQR, 0.9–3.0); 46% had ≥1.5 D. Anti-VEGF treated eyes showed less myopia (p<0.009), with no BCVA or astigmatism difference (p=0.997, p=0.271) compared to laser-treated eyes. Conclusion: One-quarter of the eyes exhibited good visual acuity (Snellen BCVA of 20/20 or better) 5 years post-ROP treatment. Refractive errors were common. Anti-VEGF therapy may be superior to laser therapy in terms of myopic refractive error.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 77%